Asset profile
zelicapavir
Small molecule
Evidence outlook · results not reported
NCT04633187 · Respiratory Syncytial Virus Infection
The lead study uses a design that frequently fails to replicate under controlled conditions, and its results have not been reported. This tier describes the design, not an outcome.
NCT04633187: This trial enrolled only 9 patients (5 on drug, 4 on placebo) and ended without reaching a larger planned size, so it was severely underpowered for its primary comparison. No statistical test was reported for the primary endpoint, and the small numeric difference (0 of 5 vs 1 of 4 patients with a complication) cannot reliably show whether the drug worked.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
2 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 2 same-indication; 1 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Zelicapavir: this drug | Phase 2 | Small molecule | — | ||
| mRESVIA | Approved | Vaccine | — | ||
| EDP-323 | Phase 2 | Small molecule | — |
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.